| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
VolitionRX (AMEX:VNRX) will release its quarterly earnings report on Thursday, 2025-08-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate VolitionRX to report an earnings per share (EPS) of $-0.05.
The market awaits VolitionRX's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
The company's EPS missed by $0.01 in the last quarter, leading to a 5.22% drop in the share price on the following day.
Here's a look at VolitionRX's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.05 | -0.07 | -0.09 |
| EPS Actual | -0.06 | -0.06 | -0.07 | -0.08 |
| Price Change % | -5.0% | -9.0% | -6.0% | 3.0% |
Shares of VolitionRX were trading at $0.6272 as of August 12. Over the last 52-week period, shares are up 8.77%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.
To track all earnings releases for VolitionRX visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VNRX
